Zionexa will present two CDx PET Tracer projects at the Upcoming annual SNMMI Meeting in Philadelphia held on June 23-26
New-York (USA) and Paris (France), June 21st, 2018 – Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, will present its latest projects at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held on June 23-26, in Philadelphia, USA.
CDx tracers are part of the precision medicine approach, allowing clinicians to have more information when making choices for the care of their patients. During this key congress for the molecular imaging world, Zionexa will present its latest projects, at the Emerging Technologies Session Monday June 25 at the Philadelphia Convention Center Room 112AB 3-5PM, focusing on EstroTep and IMAKinib-2 – EstroTep, a powerful imaging tool for metastatic breast cancer, and IMK-2 a first in class companion diagnostic for lung cancer.
EstroTep1, a biomarker for targeted diagnostic for metastatic breast cancer
With more than 250,0002 new cases in 2017 in the United-States, breast cancer is the most common cancer among women. EstroTep is a new biomarker which currently is only approved for clinical use in France for identification of estrogen receptor status in patients with metastatic breast cancer. Zionexa is currently in the process of getting the product FDA cleared in the United States.
IMAKinib-2, a first-in-class companion diagnostic for lung cancer
Zionexa’s pipeline includes other innovative, investigational new CDx molecules including a molecule targeting EGFR gene mutations in lung cancer, IMAKinib-2, generated from Oncodesign’s Nanocyclix® technology. Lung cancer is the leading cause of cancer deaths worldwide, with more than 1.6 million deaths every year.
Peter Webner, CEO Zionexa US Corp. commented, “Zionexa is honored to have been invited by the SNMMI to present part of its pipeline to the Molecular Imaging community. We firmly believe that the use of Companion Diagnostic imaging drugs can provide important information for patient care, leading to a personalized treatment and so to a better quality of life.”
The SNMMI is recognized as an international leader in promoting the value of nuclear medicine, molecular imaging and radionuclide therapy, globally. Around 6,000 attendees are expected, representing more than 60 countries.